sulfasalazine
sulfasalazine structure
|
Common Name | sulfasalazine | ||
|---|---|---|---|---|
| CAS Number | 599-79-1 | Molecular Weight | 398.393 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 689.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C18H14N4O5S | Melting Point | 260-265 °C (dec.)(lit.) | |
| MSDS | Chinese USA | Flash Point | 370.7±34.3 °C | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
Diplacone and mimulone ameliorate dextran sulfate sodium-induced colitis in rats.
Fitoterapia 101 , 201-7, (2015) Diplacone (1) and mimulone (2), two geranylated flavanones, have previously shown anti-inflammatory and antiradical activity in vitro. The present study aimed to evaluate their activity in vivo on a model of colitis induced in Wistar rats by an oral administr... |
|
|
Sulfa drugs inhibit sepiapterin reduction and chemical redox cycling by sepiapterin reductase.
J. Pharmacol. Exp. Ther. 352(3) , 529-40, (2015) Sepiapterin reductase (SPR) catalyzes the reduction of sepiapterin to dihydrobiopterin (BH2), the precursor for tetrahydrobiopterin (BH4), a cofactor critical for nitric oxide biosynthesis and alkylglycerol and aromatic amino acid metabolism. SPR also mediate... |
|
|
Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.
J. Clin. Pharmacol. 55(1) , 10-6, (2014) During antibiotic treatments, active residuals reaching the colon profoundly affect the bacterial flora resulting in the emergence of resistance. To prevent these effects, we developed an enteric-coated formulated activated-charcoal based product, DAV132, mea... |
|
|
Hypoxia-inducible factors enhance glutamate signaling in cancer cells.
Oncotarget 5(19) , 8853-68, (2014) Signaling through glutamate receptors has been reported in human cancers, but the molecular mechanisms are not fully delineated. We report that in hepatocellular carcinoma and clear cell renal carcinoma cells, increased activity of hypoxia-inducible factors (... |
|
|
On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid.
J. Pharm. Sci. 103(10) , 3171-5, (2014) Azo-bonded prodrugs of 5-aminosalicylic acid (mesalazine)-sulfasalazine, balsalazide, and olsalazine, which are used in the treatment of ulcerative colitis, rely on colonic bacteria to cleave the azo bond and liberate the active drug in the large intestine. T... |
|
|
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Mol. Cell. Biol. 34(18) , 3421-34, (2014) The ubiquitin-proteasome pathway degrades ubiquitinated proteins to remove damaged or misfolded protein and thus plays an important role in the maintenance of many important cellular processes. Because the pathway is also crucial for tumor cell growth and sur... |
|
|
Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs.
Toxicol. In Vitro 28(5) , 759-68, (2014) We established a luciferase reporter assay system, the Multi-ImmunoTox Assay (MITA), to evaluate the effects on key predictivein vitro components of the human immune system. The system is composed of 3 stable reporter cell lines transfected with 3 luciferase ... |
|
|
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Ann. Rheum. Dis. 74(1) , 27-34, (2015) To compare the efficacy and safety of intensive combination strategies with glucocorticoids (GCs) in the first 16 weeks (W) of early rheumatoid arthritis (eRA) treatment, focusing on high-risk patients, in the Care in early RA trial.400 disease-modifying anti... |
|
|
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.
Pharmacogenet. Genomics 24(8) , 409-25, (2014)
|
|
|
Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.
Scand. J. Rheumatol. 44(1) , 74-9, (2015) Microsomal prostaglandin E synthase-1 (mPGES-1) is a terminal enzyme in the production of prostaglandin E2 (PGE2) and its expression is upregulated during inflammation. mPGES-1 is considered as a potential drug target for the treatment of arthritis to reduce ... |